Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

AMP v Myriad: the Supreme Court gives a win to personalized medicine.

Klein RD.

J Mol Diagn. 2013 Nov;15(6):731-2. doi: 10.1016/j.jmoldx.2013.09.002.

2.

Our shared code: the Myriad decision and the future of genetic research.

Levy S.

Environ Health Perspect. 2013 Aug;121(8):A250-3. doi: 10.1289/ehp.121-a250. No abstract available.

3.

US Supreme Court hears arguments in case of BRCA1 and BRCA2 [corrected] patents.

McCarthy M.

BMJ. 2013 Apr 17;346:f2446. doi: 10.1136/bmj.f2446. No abstract available. Erratum in: BMJ. 2013;346:f2543.

PMID:
23596230
4.
5.

Intellectual property. Supreme Court rules out patents on 'natural' genes.

Marshall E.

Science. 2013 Jun 21;340(6139):1387-8. doi: 10.1126/science.340.6139.1387. No abstract available. Erratum in: Science. 2013 Aug 23;341(6148):842.

PMID:
23788772
6.

Data disclosure crucial after DNA patent verdict.

de Costa A.

Science. 2013 Aug 30;341(6149):959. doi: 10.1126/science.341.6149.959-a. No abstract available.

PMID:
23990544
7.

Challenging gene patents. Myriad ruling will impact personalized medicine.

Lee J.

Mod Healthc. 2013 Apr 15;43(15):8-9. No abstract available.

PMID:
23738477
8.

Gene patents, patenting life and the impact of court rulings on US stem cell patents and research.

Matthews KR, Cuchiara ML.

Regen Med. 2014 Mar;9(2):191-200. doi: 10.2217/rme.13.93. Review.

PMID:
24750060
9.

Supreme Court ruling broadens BRCA testing options.

Azvolinsky A.

J Natl Cancer Inst. 2013 Nov 20;105(22):1671-2. doi: 10.1093/jnci/djt342. Epub 2013 Nov 6. No abstract available.

PMID:
24198329
11.

US Supreme Court is asked to rule on validity of patents on BRCA1 and BRCA2 genes.

Dyer C.

BMJ. 2012 Oct 2;345:e6624. doi: 10.1136/bmj.e6624. No abstract available.

PMID:
23033368
12.

Gene patents and personalized cancer care: impact of the Myriad case on clinical oncology.

Offit K, Bradbury A, Storm C, Merz JF, Noonan KE, Spence R.

J Clin Oncol. 2013 Jul 20;31(21):2743-8. doi: 10.1200/JCO.2013.49.7388. Epub 2013 Jun 13.

13.

The Federal Circuit's decision in Myriad: isolated DNA molecules are patentable subject matter.

Ogden SR.

Am Univ Law Rev. 2011;61(2):443-56. No abstract available.

PMID:
25335196
14.

Supreme Court will rule on whether patents for BRAC1 and BRAC2 genes are valid.

Dyer C.

BMJ. 2012 Dec 5;345:e8266. doi: 10.1136/bmj.e8266. No abstract available.

PMID:
23223689
15.

Intellectual property. In a flurry of metaphors, justices debate a limit on gene patents.

Marshall E.

Science. 2013 Apr 26;340(6131):421. doi: 10.1126/science.340.6131.421. No abstract available.

PMID:
23620028
16.

Gene patenting--the Supreme Court finally speaks.

Kesselheim AS, Cook-Deegan RM, Winickoff DE, Mello MM.

N Engl J Med. 2013 Aug 29;369(9):869-75. doi: 10.1056/NEJMhle1308199. Epub 2013 Jul 10. No abstract available.

17.

Genes can't be patented, rules Supreme Court.

McCarthy M.

BMJ. 2013 Jun 14;346:f3907. doi: 10.1136/bmj.f3907. No abstract available.

PMID:
23771229
18.

Intellectual Property in Genetic Material.

Gatley I.

J Bioeth Inq. 2015 Dec;12(4):561-4. doi: 10.1007/s11673-015-9672-2. No abstract available.

PMID:
26691916
19.

Myriad case heads back to Court of Appeals: Supreme Court remands case after Prometheus decision.

[No authors listed]

Am J Med Genet A. 2012 Jul;158A(7):xi. doi: 10.1002/ajmg.a.35522. No abstract available.

PMID:
22711654
20.

Do recent US Supreme Court rulings on patenting of genes and genetic diagnostics affect the practice of genetic screening and diagnosis in prenatal and reproductive care?

Chandrasekharan S, McGuire AL, Van den Veyver IB.

Prenat Diagn. 2014 Oct;34(10):921-6. doi: 10.1002/pd.4445. Epub 2014 Jul 31. Review.

Supplemental Content

Support Center